Immunome Q3 net loss $47.1M, cash $240.1M; AL102 topline data H2 2025

Immunome Inc.

2024-Q3 EPS reported -$3.72 revenue$6,303,000

Net loss of $47.1M for Q3 2024; cash, equivalents and marketable securities $240.1M as of Sept 30, 2024.
R&D expenses $37.2M; in-process R&D $6.7M (related to business development); G&A $9.5M.
Phase 3 RINGSIDE Part B for AL102 fully enrolled; topline data expected H2 2025.
IND submissions for IM-1021 and IM-3050 on track for Q1 2025.
Cash runway expected to extend into 2026.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.